Tiara Rahayu

Tiara is Biotechnology enthusiast. Loving the world with collaboration in science, content creator, leadership in community, moderator event, and science communicator. My interests are about Biomedical informatics, genetic for disease, cancer genomics and precision oncology such as biomarkers. I have a sharing platform on @ngolabs for expand my network and get out more knowledge. Now, I’m being student research in National Research and Innovation Agency for handling Biomarker of HPV.

Anna Duraj-Thatte

Anna Duraj-Thatte received her Ph.D. from Georgia Institute of Technology, wherein she worked on protein engineering and directed evolution. Then she pursued her postdoctoral research at Wyss Institute, Harvard University. Dr. Duraj-Thatte’s research focuses on designing and developing novel strategies to produce smart engineered living materials (ELMs) by integrating the fields of synthetic biology, materials engineering, nanotechnology, and artificial intelligence (AI). Over the last eight years, she has been developing the field of ELMs by demonstrating one of the first examples of therapeutic living materials and macroscopic transient self-regenerating
materials for environmental applications. Her research work has also been featured in global media outlets, including The New York Times, The Washington Post, Smithsonian Magazine, New Scientist, CBS Boston, and Science Alert. She received the Grand Prize in the American National Science Foundation (NSF) Idea Machine competition. She was also selected as a Deep Tech Pioneer and member of Harvard Innovation Lab’s Venture Incubation Program.

Elibio Rech

Elibio Rech, a molecular engineer, geneticist, Researcher at EMBRAPA, and Director of the National Institute of Science and Technology in Synthetic Biology, developed gene transfer technologies to produce commercial genetically modified plant products. Aim to contribute to the design, construction, and engineering of synthetic genomes, cell-free protein expression, and building cell and synthetic genetic circuits, combining top-down and bottom-up approaches within the synergies and intersections of the recombinant DNA technology for synthetic domestication of specific traits from biodiversity.

Theresa Loveless

Theresa Loveless received her Ph.D. in Cell Biology from UCSF, where she studied the molecular biology of DNA replication and the DNA damage response. As a postdoctoral researcher in synthetic biology, in the laboratory of Chang Liu at UC Irvine, she made DNA recorders, synthetic biology tools that transform transient events in a cell’s life into durable changes in a small “recording” region of the cell’s genome. Theresa just started her independent laboratory in the Department of BioSciences at Rice University. The goal of the lab is to make DNA recorders that document the activation history of many signaling pathways in parallel, in physiological settings, over the whole timescale of developmental processes. These recorders will make it possible to study how transient events that are experienced heterogeneously across populations of cells affect the later behavior of each cell. Theresa is a Leading Edge Fellow and a MOSAIC K99/R00 Scholar.

NextGen Omics US 2024

Don’t miss NextGen Omics US 2024! Join leading omics experts and researchers for a two-day event delivering therapeutic innovation, applications, and technologies in NGS, clinical diagnostics, multi-omics, and single cell and spatial analyses.

Returning for the 9th year, the 2024 event again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook. Connect, collaborate, and innovate with global academic and research organisations, as well as pharma representatives, for high-level discussions.

Mark your calendar to be part of this dynamic gathering!

Synthetic Biology US 2024

Don’t miss Synthetic Biology US 2024! Join leading omics experts and researchers for a two-day event accelerating the development of synthetic biology tools to enable effective therapeutics development.

Returning for the 3rd year, the 2024 event again brings together a panel of prominent leaders and scientists, sharing new case studies, original data and industry outlook. Connect, collaborate, and innovate with global academic and research organisations, as well as pharma representatives, for high-level discussions on pioneering approaches to developing advanced synthetic biology tools for target discovery, production optimisation, AI/ML approaches as well as synthetic biology-based therapeutics case studies.

Mark your calendar to be part of this dynamic gathering!

3rd Annual Oligonucleotides Congress

Oxford Global’s 3rd Annual Oligonucleotides Congress, 13 – 15 March 2023, London, UK, will be attended by over 500 industry innovators to network about the latest advancements in oligonucleotide chemistry. Key leaders will be delving into novel platforms & technologies for the successful delivery of oligonucleotides, the development of greener synthetic processes, as well as innovative computational approaches & methods for discovery and analytical development.

Alongside our in-depth presentations will be regular networking breaks, giving you the chance to connect and collaborate with other experts in your field and learn more about solutions and services on offer to accelerate your work.

Co-located with the 17th Annual Proteins & Antibodies Congress, 11th Annual Peptides Congress and 2nd Annual Sustainability in Biologics Congress, these events will deliver over 80 exciting industry presentations across 3 days and providing unparalleled opportunity for high level scientific discussion.

Biomarkers 2024

Europe’s flagship event for Biomarker Research Returns: the must-attend forum to engage with the latest trends transforming biomarker and translational research.

Organ Modelling and 3D Cell Culture 2024

Connecting leaders in drug discovery to optimise organ modelling techniques and facilitate advanced applications.

Formulation & Delivery 2024

Learn from and meet leading experts in pharmaceutical science, addressing the critical strategic advances and technical innovation in formulation, drug delivery, RNA therapeutics & inhaled therapies.

The 2024 event will be opened by the highly acknowledged expert Thomas von Erlach, Chief Scientific Officer at Vivtex highlighting Drug Delivery Systems For Biologics. This is the event to attend to stay ahead of the curve.

Key focuses this year include:
Small Molecule Drug Formulation – showcasing AI-driven automation in formulation processes and a panel on the ongoing progress in sustainable manufacturing

Biologics Drug Delivery – encompassing strategies for improved oral delivery and a feature workshop on characterisation of exosomes for drug delivery

Bioanalysis: Stability, Characterisation, Developability – covering protein characterisation, aggregation prevention, and digital twins for advanced lyophilisation

Small Molecule Drug Delivery – highlighting a workshop on PROTAC drug delivery for improved bioavailability and enhanced targeting

Biologics and New Modalities Formulation – emphasising advances in vaccine formulations and longer-acting forms

Elizabeth Kellogg

Elizabeth Kellogg did her undergraduate studies at UC Berkeley and received a PhD from the University of Washington, working on computational biology in the group of David Baker. She then became a postdoctoral fellow in the lab of Eva Nogales at UC Berkeley using cryo-electron microscopy. Her scientific background results in a scientific approach that seeks to understand biology with a quantitative perspective, relying on biological structure determination and design. Since starting her own group at Cornell University in 2019, Dr. Kellogg has sought to understand how transposons reshape genomes and how they can be repurposed as genome-editing tools. In particular, her group has investigated the behavior and molecular mechanisms of programmable, CRISPR-associated transposons (CASTs), to determine how DNA integration is regulated spatially and temporally in a genomic context, using a combination of biochemical, structural, single-molecule and genetic approaches. Among other honors, Dr. Kellogg was selected as Pew Biomedical Scholar in 2021 and received the 2023 Margaret Oakley Dayhoff Award from the Biophysical Society. She joined St. Jude as an Associate Member in 2023.

Janet Standeven

An educator with 28 years of classroom experience in Core Sciences, Social Sciences and Biotechnology. Founded the Lambert iGEM program in 2012. In 2022 Lambert’s team was named the Grand Prize Winner of the iGEM Jamboree. The iGEM competition is the leading collegiate competition in the field of synthetic biology. She is a 2022 recipient of a NIH SEPA grant with Dr. Bhamla of Georgia Institute of Technology. In collaboration with members of the Bhamla lab she leads students in research and development of synthetic biology projects that also include hardware and software components. Ongoing projects include the ElectroPen, a 23 cent electroporator and other frugal devices for extraction of DNA and quantification of data.
Ms. Standeven received a BA in Anthropology and Social Studies Teaching Certificate from Millersville University of Pennsylvania. She earned her Master of Chemical Life Science from the University of Maryland in 2013. During her master’s studies she was a recipient of a G.I.F.T. fellowship with the Styczynski Group at Georgia Institute of Technology and subsequently received RET, support with the Styczynski group from 2014-2018. She is a recipient of numerous teaching awards and recognitions including Teacher of the Year in 2011 for Riverwatch Middle School, 2018 for Lambert High School, Forsyth County School STAR teacher in 2019 and 2023, in addition to being recognized as Biotechnology Teacher of the Year in Georgia for 2016. She was an attendee at the White House Bioeconomy Summit in 2019. She currently participates on the Human Practices committee for the iGEM foundation and serves as a Master Teacher for GABIO’s Rural Teacher Training Initiative.

Gozde Demirer

Gozde was born and raised in Istanbul, Turkey and received her B.S. in Chemical and Biological Engineering from Koc University in 2015. Gozde completed her Chemical Engineering Ph.D. at UC Berkeley with Prof. Markita Landry in 2020. During her Ph.D. studies, she developed nanotechnologies for plant genetic engineering. For her postdoctoral work, Gozde joined Prof. Siobhan Brady’s lab at UC Davis, where she studied nutrient use efficiency of tomato and developed high-throughput functional genomics tools to study transcriptional regulation in crops.

Joshua Atkinson

Dr. Atkinson’s research aims to use approaches from synthetic biology, protein engineering, biophysics and electrochemistry to understand and control how microbes and proteins transport electrons. The Atkinson Lab seeks to elucidate the critical role electron transport plays in energy and information processing in cells and microbial communities and to use this knowledge to engineer new biotechnologies that address societal challenges in sustainability, environmental monitoring & remediation, chemical synthesis, and resource recovery & extraction. Areas of current emphasis are the development and application of design rules for (i) how microorganisms use proteins to regulate electron transfer in metabolic networks, (ii) how electron flows shape the structure of microbial communities that impact geochemical cycles, and (iii) how living electronic materials can be built that couple the information processing and catalytic capabilities of biology with electrochemical devices.

Ilenne Del Valle

Ilenne Del Valle is a Research Staff Scientist at Oak Ridge National Laboratory. She earned her Bachelor’s degree in Biochemistry from the University of Chile and her Ph.D. in Systems, Synthetic, and Physical Biology from Rice University, where she worked in the Silberg and Masiello lab. Following her Ph.D., she served as a postdoctoral researcher in the Eckert lab at ORNL. Currently, her research focuses on engineering new synthetic biology tools to facilitate ecosystem engineering, with a specific emphasis on environmental, energy, and sustainability applications.

Leili Rohani

Dr. Leili Rohani is a Stem Cell Scientist at the School of Biomedical Engineering, University of British Columbia, and upcoming Research Scientist at MIT Synthetic Biology Center and Department of Biological Engineering. Her research has been focused on stem cells, regenerative medicine, cell therapy, and cell-fate engineering with the intent to provide a platform for future gene and precision therapies for heart diseases. She is passionate about combining tissue engineering, single-nuclei RNA sequencing and synthetic biology tools to create a human single cell atlas of heart disease as a basis for understanding, diagnosing, monitoring, and treating heart diseases. Her end goal is to look at the SynBio platform (tissue engineering, single nuclei RNAseq, synthetic biology) as a new vocabulary for disease studies to determine the ways in which cells and disease genes act, which cells are disrupted in disease, which programs change in them, what mechanisms underlie their (dis)regulation, how their cell-cell communications are affected, and what would be the impact of therapies. Beyond her research, she is passionate about science communication, networking, and collaboration.

Cameron Kim

Cameron Kim is an Assistant Professor of the Practice in Biomedical Engineering at Duke University and member of the Duke Center for Advanced Genomic Technologies. He received his Ph.D. in Bioengineering at Stanford where he studied protein and RNA-based control systems within alternative splicing devices for mammalian synthetic biology applications. Since coming to Duke in 2020, Dr. Kim has been researching ethics-guided design frameworks for emergent biotechnologies, including gene and cell-based therapies, to improve the classroom experience for biomedical engineering students through team and project-based learning. He serves as the research advisor for the Duke International Genetically Engineered Machine undergraduate research group to promote authentic research experiences and mentor the next generation of bioengineers. Currently, Dr. Kim and his undergraduate team of 15 students are initiating a project on developing high-throughput screening of novel protein secretion signals to stimulate chimeric antigen receptor T cells for signal amplification. He also serves as the Associate Director for Undergraduate Studies in Biomedical Engineering. In recognition of his teaching, he received the Bass Connections Leadership Award and the Klein Family Distinguished Teaching award in 2023. Overall, his work aims to advance the field of biomedical engineering through innovative education and research, with a focus on improving society through emergent biotechnologies.

Immuno US 2023

Featuring 30+ presentations, the event brings together over 120 attendees from leading pharma, biotech and academic organisations designing innovative strategies and technologies for more effective cancer immunotherapy development.

Expand your knowledge & discuss future priorities in:

Discovery & Development: Cell Therapies & Antibody Approaches
Biomarkers, Precision Medicine & Spatial Biology in Immuno-Oncology
Discovery & Development: Intra-tumoral Immuno & Combination Therapies & Small Molecules as IO Therapies
Translational & Preclinical and Clinical Development

View the agenda here – https://www.oxfordglobal.co.uk/immuno-series-us/agenda/?utm_source=ebrc&utm_medium=eventlisting&utm_campaign=immuno&utm_content=immunous2023

Co-located with Biomarkers US 2023 attendees receive access to both events. For more information contact marketing@oxfordglobal.co.uk

Targets and Cell Types in Immuno-Oncology Europe 2023

With new & emerging targets and drug candidates in immuno-oncology, key opinion leaders from pharmaceutical & biotech companies as well as academic & research organisations will be presenting on innovative approaches & methods for target identification & validation, such as AI-based strategies, novel checkpoint inhibitors and latest developments & case studies in cellular therapies : TILs, gamma deltas, myeloid cells.

Expand your knowledge & discuss future priorities in:
– Emerging Technologies, Strategies & Methods for Novel Targets & Target Validation in Immuno-Oncology
– Novel Cell Types to Develop Effective IO Therapies

View the agenda:https://www.oxfordglobal.co.uk/immuno-targets-cells/agenda/?utm_source=ebrc&utm_medium=eventlisting&utm_campaign=immuno&utm_content=tacell2023

Co-located with Biomarkers Europe 2023 and Precision Oncology Europe 2023, attendees will receive access to all three events. For more information contact marketing@oxfordglobal.co.uk

RNA Therapeutics & Delivery 2023

Join RNA leaders, experts and distinguished scientists in Europe, delivering breakthrough research, technologies & connecting global pharma, biotech and academia for high-level discussions on the latest innovations within the formulation and delivery of RNA-based therapeutics.

Back to top ⇑